Advances in medical sciencesHumansInfliximabMaleFemaleAdult
The transition from intravenous to subcutaneous infliximab in a cohort of patients with inflammatory bowel disease: results of the INESTIMABLE retrospective observational study.
Alessia Todeschini, Andrea Geccherle, Paola Signoretto, Nicoletta Colaci, Federica Mellone, Nicoletta De Santis, Massimo Guerriero, Giuliano Barugola, Angela Variola
Published: 202510.1016/j.advms.2025.10.001
Abstract
PURPOSE: This study aimed to present real-world data regarding the treatment of inflammatory bowel disease (IBD) with the subcutaneous (SC) formulation of the tumor necrosis factor inhibitor, infliximab. METHODS: Adult IBD patients who switched from…
Preview only. Read the full abstract at the source